{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:22:20Z","timestamp":1777098140646,"version":"3.51.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.xops.2025.100800","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T01:29:26Z","timestamp":1745112566000},"page":"100800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase I Study of the Anti-interleukin 33 Fragment Antigen-Binding Region RO7303359 in Geographic Atrophy Secondary to Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"5","author":[{"given":"Joel A.","family":"Pearlman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veeral S.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arshad M.","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahan B.","family":"Indjeian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Brunstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denison","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall","family":"Dere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Datta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry E.","family":"Wiley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2025.100800_bib1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","article-title":"Geographic atrophy: clinical features and potential therapeutic approaches","volume":"121","author":"Holz","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.100800_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0002-9394(86)90535-0","article-title":"Geographic atrophy of the retinal pigment epithelium","volume":"102","author":"Maguire","year":"1986","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2025.100800_bib3","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.xops.2025.100800_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"issue":"5-a Suppl","key":"10.1016\/j.xops.2025.100800_bib5","first-page":"S2","article-title":"Geographic atrophy: mechanism of disease, pathophysiology, and role of the complement system","volume":"29","author":"Bakri","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.xops.2025.100800_bib6","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2025.100800_bib7","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.xops.2025.100800_bib8","doi-asserted-by":"crossref","first-page":"155891","DOI":"10.1016\/j.cyto.2022.155891","article-title":"Interleukin-33 (IL-33): a critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine","volume":"156","author":"Cayrol","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.xops.2025.100800_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1084\/jem.20150894","article-title":"IL-33 amplifies an innate immune response in the degenerating retina","volume":"213","author":"Xi","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.xops.2025.100800_bib10","doi-asserted-by":"crossref","first-page":"5230716","DOI":"10.1155\/2020\/5230716","article-title":"The functional roles of IL-33\/ST2 Axis in ocular diseases","volume":"2020","author":"Qian","year":"2020","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.xops.2025.100800_bib11","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood-2009-02-203372","article-title":"Interleukin-33 induces angiogenesis and vascular permeability through ST2\/TRAF6-mediated endothelial nitric oxide production","volume":"114","author":"Choi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.xops.2025.100800_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/path.4816","article-title":"Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in the eye","volume":"241","author":"Theodoropoulou","year":"2017","journal-title":"J Pathol"},{"key":"10.1016\/j.xops.2025.100800_bib13","first-page":"2718","article-title":"Development of IL-33\/ST2 pathway activity biomarkers and their evaluation in patients with geographic atrophy secondary to AMD","volume":"64","author":"Indjeian","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525000983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525000983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T19:44:15Z","timestamp":1772048655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914525000983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2666914525000983"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2025.100800","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Study of the Anti-interleukin 33 Fragment Antigen-Binding Region RO7303359 in Geographic Atrophy Secondary to Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2025.100800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100800"}}